A new vaccine provided complete protection, in nonhuman primates, against three types of equine encephalitic viruses that are possible bioterrorism agents.
Concern over Venezuelan equine encephalitis virus has prompted the US Department of Defense (DoD) to invest $2.5 million into a related research grant.
Researchers, studying respiratory infections in Peru, identified Venezuelan equine encephalitis virus (VEEV) in a nasopharyngeal swab, indicating that this alphavirus can be present in human respiratory secretions.
A manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, demonstrated success in the development of a Venezuelan Equine Encephalitis Virus vaccine.
The US Army Joint Vaccine Acquisition Program has awarded two contracts to test and manufacture a potential new vaccine against Venezuelan equine encephalitis (VEE).
This sheet offers an overview of the aetiology, epidemiology, and diagnoses of Venezuelan equine encephalitis.
Researchers have exploited a weakness in Venezuelan equine encephalitis virus’ (VEEV) genetic code, which results in a far less deadly version of the virus.